New research shows women with obesity and heart failure lose more weight with Wegovy than men. Discover the findings and see how it can help you!

New Research Shows Wegovy May Help Women Lose More Weight Than Men

  • A recent study found that women lost more weight on average than men while taking Wegovy.
  • Several factors may explain this difference, like metabolism, fat storage patterns, societal pressures, or genetics. More research is needed.
  • However, both men and women saw similar improvements in their heart failure symptoms.
  • Obesity is thought to potentially cause the type of heart failure studied.
  • Experts say by promoting weight loss, Wegovy could help lower women’s risk of dying from heart disease in the future.

This study suggests Wegovy may be slightly more effective for weight loss in women versus men. But it benefited certain heart health measures equally. Reducing obesity can lower risks of heart failure down the road, especially for women. More analysis is still needed on the gender differences.

A study in the Journal of the American College of Cardiology looked at the weight loss drug Wegovy (semaglutide) in people with a type of heart failure called HFpEF.

HFpEF makes the heart stiff, so it can’t pump blood as efficiently despite normal ejection fraction. Obesity is thought to be a potential cause. Women face higher HFpEF risks.

The findings:

  • Women lost more weight on average with Wegovy compared to men.
  • But both genders saw similar improvements in their heart failure symptoms.

While Wegovy promoted greater weight loss for females, it benefited men’s heart health too. This suggests the drug works through mechanisms beyond just fat loss.

Experts think Wegovy could lower women’s future chances of dying from heart disease by reducing obesity. Further research is still needed on the gender differences.

Wegovy Yields Greater Weight Loss Without Added Benefits

The study included two trials with 1,145 people who have HFpEF. About half were female who tended to have higher BMI and worse symptoms than males.

For 1 year, participants either got 2.4 mg of Wegovy or a placebo weekly.

The results:

  • Females lost more weight – 9.6% vs 7.2% for males.
  • But both genders saw similar 7.5 point improvement in heart failure symptoms.

As Reuters reported, the scientists found this surprising. They expected greater symptom relief with more weight loss in females.

In plain terms, while Wegovy promoted more weight loss for women, the improvement in their heart health was on par with men who lost less weight.

This suggests Wegovy provides benefits beyond just fat loss. Other mechanisms related to heart function are likely involved.

Why Wegovy Promotes More Weight Loss for Females

Dr. John Lowe commented that the greater weight loss for women may stem from metabolic and hormonal differences between the sexes.

“Females tend to store more fat in different patterns, which could better respond to how this medication works,” he explained.

Research also shows women often react differently in weight loss trials. Social expectations and pressures may increase their adherence to treatments and lifestyle changes, enhancing Wegovy’s effects.

Genetic variations that influence drug response could also be a factor, according to Dr. Lowe. Pharmacogenomics studies reveal individuals can metabolize medications differently based on their genes.

In summary, factors like metabolism, fat storage, social influences, and genetics may all contribute to Wegovy’s increased weight loss benefits for women. More studies are needed to better understand the mechanisms involved.

How Wegovy Could Lower Women’s Heart Disease Risk

As Dr. Michael McKinney explains, obesity significantly raises risks for cardiovascular disease – the top cause of death for both men and women.

“By promoting weight loss for obese women, Wegovy could play a key role in reducing this threat,” he said. “Losing weight helps lower blood pressure, cholesterol, and inflammation.”

For women with obesity and heart issues, weight loss may improve condition management and reverse consequences of excess weight.

“If Wegovy works better in women, it could be an amazing strategy to control body weight and cut future heart problems,” noted Dr. McKinney.

These promising findings suggest optimizing treatments for women’s physiology could strengthen healthcare by lowering female heart disease mortality.

By targeting obesity, Wegovy may help lower risks of developing cardiovascular disease down the road, especially for high-risk women. But more research is still needed on its long-term protective effects.

New Study Finds Wegovy Leads to More Weight Loss in Women with Heart Failure

  • Females with obesity and a type of heart failure called HFpEF lost more weight using Wegovy versus males.
  • But both genders saw similar improvements in their heart failure symptoms.

What may explain the greater weight loss in women? Experts suggest:

  • Differences in metabolism, fat storage patterns, social pressures, genetics. More research needed.

Importantly, since obesity raises women’s risk of this heart condition and heart disease is the #1 killer:

  • Wegovy could potentially help lower women’s chances of dying from heart disease by reducing obesity.

Wegovy seems to promote more weight loss for women based on this study. But it benefited men’s heart health too. Lowering obesity can cut future heart risks, especially in high-risk women.

More resources:

Share.
Leave A Reply